LIFESCI PHARMACEUTICALS INC has a total of 50 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2014. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are BEIJING LABWORLD BIO MEDICINE TECHNOLOGY CO LTD, ISOCURE BIOSCIENCES INC and FORESEE PHARMACEUTICALS USA INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | WIPO (World Intellectual Property Organization) | 11 | |
#3 | EPO (European Patent Office) | 7 | |
#4 | Canada | 6 | |
#5 | Australia | 3 | |
#6 | China | 3 | |
#7 | Brazil | 2 | |
#8 | EAPO (Eurasian Patent Organization) | 2 | |
#9 | Republic of Korea | 2 | |
#10 | Mexico | 2 | |
#11 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Mcdonald Andrew | 45 |
#2 | Qian Shawn | 38 |
#3 | Andrew Mcdonald | 5 |
#4 | Kalfus Ira | 3 |
#5 | Shawn Qian | 2 |
Publication | Filing date | Title |
---|---|---|
EP3758702A1 | Treatment of hereditary angioedema | |
WO2019142053A2 | Therapeutic inhibitory compounds | |
WO2018229543A2 | Therapeutic inhibitory compounds | |
WO2018015818A2 | Therapeutic inhibitory compounds | |
EP3481391A1 | Therapeutic inhibitory compounds | |
WO2017098328A2 | Therapeutic inhibitory compounds | |
EP3317241A2 | Therapeutic inhibitory compounds | |
EP3317259A2 | Therapeutic inhibitory compounds | |
US2016200704A1 | Therapeutic inhibitory compounds | |
KR20170034902A | Therapeutic inhibitory compounds | |
EA032713B1 | Therapeutic inhibitory compounds |